Phase III trial for KLU156 (ganaplacide/lumefantrine, or GanLum), meets primary endpoint of non-inferiority to standard of care Coartem® (artemether-lumefantrine) Demonstrates PCR-corrected cure rate ...
First to have delivered at scale, Novartis fortifies leadership in RLT innovation and infrastructure with California facility, additional plans for Florida and Texas ...
Explore opportunities with Novartis and Sandoz below. For additional roles with Novartis Gene Therapies (formerly AveXis) visit the GTx Career Search.
Novartis works with the patient community around the world to discover new ways to improve and extend people’s lives. Novartis works closely with healthcare professionals around the world to support ...
Albania Algeria Angola Argentina Armenia Australia Austria Azerbaijan Bahamas Bahrain Bangladesh Barbados Belarus Belgium Benin Bermuda Bolivia Bosnia and Herzegovina Brazil Bulgaria Burkina Faso ...
Cosentyx® (secukinumab) achieved statistically significant and clinically meaningful sustained remission vs placebo at Week 521 Trial showed reduction in annual cumulative steroid dose vs placebo ...
Die neue Zellkulturanlage wird therapeutische Proteine für den Einsatz in innovativen Therapien produzieren und entspricht den höchsten Produktions- und Umweltstandards Die Eröffnung der Anlage in ...
Assoc. Dir. DDIT DEV Data Analytics DS&AI Regular, Full time Information Technology India Hyderabad Office Nov 13, 2025 ...
V Novartisu spodbujamo inovativnost in razvoj ter delujemo na številnih področjih. Tudi vi lahko postanete del tega, del naše zgodbe. Pridružite se naši ustvarjalni skupnosti strokovnjakov in našli ...
Εξερευνήστε ευκαιρίες στη Novartis και στη Sandoz παρακάτω. Για επιπλέον ρόλους στη Novartis Gene Therapies (πρώην AveXis) επισκεφτείτε την Αναζήτηση ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback